Views & Analysis The future of healthcare: the patient advocate and investor ... Examining the views of different stakeholders in the ecosystem supporting drug R&D.
Views & Analysis Access and elimination: the future of DAAs in hepatitis C How direct-acting antivirals are transforming treatment of hepatitis C.
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
Debates & Insight Sponsored The hepatitis C conundrum: balancing cost and affordability An estimated 2–3% of the world’s population is living with hepatitis C virus (HCV) – a condition that, when left untreated, can cause life-threatening damage to the liver.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.